| Autor: |
Stefanelli A; Institute of Nuclear Medicine, Catholic University of the Sacred Heart, Largo Gemelli, 8, 00168 Rome, Italy., Treglia G, Mirk P, Muoio B, Giordano A |
| Jazyk: |
angličtina |
| Zdroj: |
ISRN gastroenterology [ISRN Gastroenterol] 2011; Vol. 2011, pp. 824892. Date of Electronic Publication: 2011 Aug 14. |
| DOI: |
10.5402/2011/824892 |
| Abstrakt: |
Aim. (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) is a powerful tool for staging and defining "good responders" to chemotherapy in tumor setting. Gastrointestinal stromal tumors (GISTs) are sarcoma involving gastrointestinal tract and may require a chemotherapy including imatinib, a tyrosine kinase inhibitor agent. Some GIST patients become refractory to imatinib; therefore, other tyrosine kinase inhibitors or concomitant chemotherapy may be considered for treatment. The aim of this paper is to assess if (18)F-FDG PET imaging is a useful tool to evaluate treatment response to new chemotherapies beyond imatinib for GIST patients. Methods. We performed a review of the literature about the role of (18)F-FDG PET in the evaluation of treatment response to new chemotherapies beyond imatinib for GIST patients. Results and Conclusions. (18)F-FDG PET seems to be able to assess therapy response earlier than computed tomography (CT) imaging in imatinib refractory GIST patients treated with other agents. However, a dual modality PET-CT imaging is recommendable to achieve a better detection of all lesions. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
